Tianyi Medical: The company's new product, Sodium Bicarbonate Hemofiltration Replacement Solution, has obtained a drug registration certificate.

Tianyi Medical Announcement: Subsidiary Tianyi Pharmaceutical recently received the "Drug Registration Certificate" issued by the National Medical Products Administration. The name of the drug is Sodium Bicarbonate Hemofiltration Solution, with approval number H20263628, valid until March 16, 2031. This product is used for continuous renal replacement therapy and can be directly connected to the machine for use. It is suitable for critically ill patients who require long-term, continuous renal replacement therapy. This approval marks the company's successful extension of its product line into the field of blood filtration replacement solutions, contributing to the enhancement of the company's brand influence and market competitiveness in the field of blood purification.